Research programme: granulocyte-macrophage colony-stimulating factor - Bolder BioTechnology

Drug Profile

Research programme: granulocyte-macrophage colony-stimulating factor - Bolder BioTechnology

Alternative Names: BBT-007; GM-CSF - Bolder BioTechnology; PEG-GM-CSF - Bolder BioTechnology; PEG-granulocyte-macrophage colony stimulating factor - Bolder BioTechnology

Latest Information Update: 04 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bolder BioTechnology
  • Class Granulocyte-macrophage colony-stimulating factors; Polyethylene glycols
  • Mechanism of Action Immunomodulators; Neutrophil stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute radiation syndrome; Alzheimer's disease; Neutropenia

Most Recent Events

  • 04 Dec 2017 Granulocyte-macrophage colony stimulating factor is still in preclinical development for acute radiation syndrome and neutropenia in USA (Bolder Biotechnology pipeline, December 2017)
  • 04 Dec 2017 Preclinical trials in Alzheimer's disease in USA (Parenteral) before December 2017 (Bolder Biotech pipeline, December 2017)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neutropenia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top